American Thoracic Society

Medications

IPF drug fails in new trial

A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis (IPF).

Diseases, Conditions, Syndromes

Cell division abnormality contributes to inflammation in COPD

Changes in the ability of lung cells to divide may play a role in initiating or prolonging lung tissue inflammation, a hallmark of chronic obstructive pulmonary disease (COPD), according to a study conducted by researchers ...

Sleep disorders

Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

Medical research

Research links telomere length to emphysema risk

Telomeres, the body's own cellular clocks, may be a crucial factor underlying the development of emphysema, according to research from Johns Hopkins University.

Diseases, Conditions, Syndromes

Late-breaking clinical trials

Results from C91 "Late-Breaking Clinical Trials" on Tuesday afternoon, May 17, will bring new light to clinical problems and potential treatments. While five examine possible new therapies for people with asthma (pregnant ...

page 6 from 40